title: Antinuclear antibodies as potential markers of lung cancer.
abstract: There are multiple case reports of antinuclear antibodies (ANAs) in patients with malignancies, yet to date there has not been a systematic survey of ANAs in lung cancer. We have previously reported that autoantibodies to collagen antigens resembling those found in the connective tissue diseases are consistently detected in the sera from lung cancer patients. In this work, we looked for the presence of ANAs in the sera from these same patients. Sera from 64 patients with lung cancer and 64 subjects without a history of cancer were retrospectively tested for reactivity on immunoblots of nuclear extracts of HeLa, small cell carcinoma, squamous cell carcinoma, adenocarcinoma, large cell carcinoma of the lung, and of normal lung cells. Associations were sought between the reactivities on immunoblots and lung cancer cell type, diagnosis, and progression-free survival by the method of classification and regression trees (CARTs). Cross-validated CART analyses indicated that reactivities to certain bands in immunoblots are associated with different types of lung cancer. Some of these autoantibodies were associated with a prolonged survival without disease progression. Our data suggest that autoimmunity is often a prominent feature of lung cancer and that molecular characterization of these antigens may lead to the discovery of proteins with diagnostic and prognostic value.
authors.affiliation: Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
authors.forename: F
authors.initials: F
authors.lastname: Fernández-Madrid
authors.forename: P J
authors.initials: PJ
authors.lastname: VandeVord
authors.forename: X
authors.initials: X
authors.lastname: Yang
authors.forename: R L
authors.initials: RL
authors.lastname: Karvonen
authors.forename: P M
authors.initials: PM
authors.lastname: Simpson
authors.forename: M J
authors.initials: MJ
authors.lastname: Kraut
authors.forename: J L
authors.initials: JL
authors.lastname: Granda
authors.forename: J E
authors.initials: JE
authors.lastname: Tomkiel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000974:Antibodies, Antinuclear / Q000097:blood*; D034961:Antigens, Nuclear; D014408:Biomarkers, Tumor / Q000097:blood*; D002460:Cell Line; D018572:Disease-Free Survival; D005260:Female; D006367:HeLa Cells; D006801:Humans; D015151:Immunoblotting; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000974:Antibodies, Antinuclear; D034961:Antigens, Nuclear; D014408:Biomarkers, Tumor; D009687:Nuclear Proteins